BUD31 and neoplasm: Increased expression of BUD31 [35], RIP4 [36], and RPL39 [37,38] have been previously correlated with disease malignancy and associated worse overall survival in patients with GBM, with in vitro overexpression of RPL39 associated with enhanced proliferation and migration of tumor cells [37].